64 studies found for:    Open Studies | "Tomography, Emission-Computed"
Show Display Options
Rank Status Study
1 Recruiting SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy
Conditions: Extensive Stage Small Cell Lung Cancer;   Limited Stage Small Cell Lung Cancer;   Occult Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Radiation: technetium Tc 99m-labeled macroaggregated albumin;   Drug: technetium Tc 99m DTPA;   Procedure: single photon emission computed tomography;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography
2 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
3 Not yet recruiting Prognostic Value of SPECT-imaging Myocardial Perfusion Heterogeneity
Conditions: Coronary Artery Disease;   Coronary Atherosclerosis
Intervention: Device: Stress Single Photon Emission Computed Tomography
4 Recruiting Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging
Condition: Symptomatic Coronary Artery Disease
Intervention: Procedure: Myocardial perfusion imaging
5 Recruiting 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
6 Recruiting F-18 FES PET in Measuring Hormone Expression in Patients With Recurrent or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
Conditions: Estrogen Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Radiation: F-18 16 alpha-fluoroestradiol;   Procedure: positron emission tomography;   Radiation: fludeoxyglucose F 18
7 Not yet recruiting Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Conditions: Bone Metastases;   HER2-positive Breast Cancer;   Liver Metastases;   Lung Metastases;   Recurrent Breast Cancer;   Soft Tissue Metastases;   Stage IV Breast Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Biological: trastuzumab;   Radiation: copper Cu 64-DOTA-trastuzumab;   Biological: ado-trastuzumab emtansine;   Other: laboratory biomarker analysis
8 Recruiting 123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
Conditions: Heart Failure;   Cardiomyopathy
Interventions: Radiation: AdreView;   Other: Single Photon Emission Computed Tomography
9 Recruiting Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Rituximab;   Drug: 111In Ibritumomab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumomabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
10 Not yet recruiting PET/CT for the Quantification of Atherosclerotic Plaque Inflammation
Conditions: Coronary Artery Disease;   Acute Coronary Syndrome
Interventions: Other: [18F]-FDG positron emission computed tomography;   Procedure: Invasive coronary angiography;   Procedure: Intravascular ultrasound and virtual histology;   Other: Serum biomarkers
11 Recruiting Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Conditions: Adult Angiosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18
12 Recruiting PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IIA Colon Cancer;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Procedure: positron emission tomography;   Procedure: computed tomography;   Procedure: magnetic resonance imaging;   Radiation: fludeoxyglucose F 18
13 Recruiting Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL;   Biological: dendritic cell vaccine therapy;   Biological: aldesleukin;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis
14 Recruiting Entinostat and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: entinostat;   Biological: aldesleukin;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography
15 Recruiting Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Radiation: carbon-11 acetate;   Radiation: fluorine F 18 sodium fluoride;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis
16 Recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: lenalidomide;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
17 Recruiting Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: etoposide;   Drug: cyclophosphamide;   Radiation: total marrow irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography
18 Recruiting 64Cu DOTA-Trastuzumab PET in Studying Patients With Gastric Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IA Gastric Cancer;   Stage IB Gastric Cancer;   Stage IIA Gastric Cancer;   Stage IIB Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer
Interventions: Radiation: copper Cu 64-DOTA-trastuzumab;   Device: positron emission tomography;   Other: laboratory biomarker analysis
19 Recruiting FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis
20 Recruiting FLT-PET/MRI in Measuring Early Response in Patients With Metastatic Solid Tumors Receiving Treatment That Blocks Blood Flow to the Tumor
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography;   Procedure: magnetic resonance imaging

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years